298
Views
16
CrossRef citations to date
0
Altmetric
Drug Evaluations

Erdosteine: its relevance in COPD treatment

, MD
Pages 333-343 | Published online: 16 Apr 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Mehak Passi, Sadia Shahid, Sankarakuttalam Chockalingam, Isaac Kirubakaran Sundar & Gopinath Packirisamy. (2020) Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases. International Journal of Nanomedicine 15, pages 3803-3826.
Read now
Sowmya P Lakshmi, Aravind T Reddy & Raju C Reddy. (2017) Emerging pharmaceutical therapies for COPD. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 2141-2156.
Read now
Irfan Rahman & Vuokko L Kinnula. (2012) Strategies to decrease ongoing oxidant burden in chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology 5:3, pages 293-309.
Read now

Articles from other publishers (13)

Ji W on Choi, Hyun Jee Kim, Jin Yoon, Jang-Ho Seo, Ju-Yeun Lee & Hye-Ryun Kang. (2022) A Case of Atypical Fixed Drug Eruption Induced by Erdosteine. Journal of Pharmacoepidemiology and Risk Management 14:2, pages 165-168.
Crossref
S. N. Avdeev, N. V. Trushenko, S. Yu. Chikina & O. A. Suvorova. (2022) The potential of erdosteine to reduce the rate of exacerbations of chronic obstructive pulmonary disease. PULMONOLOGIYA 32:2, pages 253-259.
Crossref
Mehmet Emrah Yaman & Alptug Atila. (2022) A rapid and sensitive UPLC–MS/MS method for quantification of erdosteine as bulk drug and in capsules as dosage forms. Macedonian Pharmaceutical Bulletin 67:2, pages 23-31.
Crossref
Da Woon Sim, Ji Eun Yu & Young-Il Koh. (2021) Fixed drug eruption and anaphylaxis induced concurrently by erdosteine: a case report. Allergy, Asthma & Clinical Immunology 17:1.
Crossref
Francesco Scaglione & Orlando Petrini. (2019) Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive?. Clinical Medicine Insights: Ear, Nose and Throat 12, pages 117955061882193.
Crossref
Mario Cazzola, Luigino Calzetta, Clive Page, Paola Rogliani & Maria Gabriella Matera. (2018) Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulmonary Pharmacology & Therapeutics 48, pages 185-194.
Crossref
Atilla Karateke, Recep Dokuyucu, Hatice Dogan, Tumay Ozgur, Zeynel Abidin Tas, Okan Tutuk, Gokhan Agturk & Cemil Tumer. (2018) Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model. Medical Principles and Practice 27:6, pages 515-522.
Crossref
P. A Shah, D. P Chaudhari, N. N Mistry & T. R Gandhi. (2017) DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR SIMULTANEOUS ESTIMATION OF ERDOSTEINE, GUAIPHENESIN AND TERBUTALINE SULPHATE USING BOX-BEHNKEN DESIGN. INDIAN DRUGS 54:12, pages 40-50.
Crossref
Aziz Mutlu Barlas, Kemal Kismet, Serap Erel, Serdar Kuru, Turgut Cavusoglu, Mehmet Senes, Zeynep Adiyaman, Pinar Celepli, Sema Hucumenoglu & Recep Pekcici. (2017) Erdosteine ameliorates the harmful effects of ischemia-reperfusion injury on the liver of rats. Acta Cirurgica Brasileira 32:10, pages 796-806.
Crossref
N Mistry, P Shah, D. Chaudhari, B. Baria & T. Gandhi. (2017) SIMULTANEOUS ESTIMATION OF ERDOSTEINE, GUAIPHENESIN AND TERBUTALINE SULPHATE IN SYRUP FORMULATION BY TWO UV SPECTROPHOTOMETRIC METHODS. INDIAN DRUGS 54:07, pages 46-51.
Crossref
R.W. Dal Negro, M. Visconti & P. Turco. (2015) Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial. Pulmonary Pharmacology & Therapeutics 33, pages 47-51.
Crossref
Irfan Rahman. (2012) Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1822:5, pages 714-728.
Crossref
H Sahin Kavakli, O Alici, C Koca, ND Altintas & M Aydin. (2017) Effects of Erdosteine in Experimental Sepsis Model in Rats. Hong Kong Journal of Emergency Medicine 18:5, pages 282-286.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.